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ABSTRACT
ObjeCtive
To improve the selection of patients with acute ischaemic 
stroke for intra-arterial treatment using a clinical decision 
tool to predict individual treatment benefit.
Design
Multivariable regression modelling with data from two 
randomised controlled clinical trials.
setting
16 hospitals in the Netherlands (derivation cohort) and 
58 hospitals in the United States, Canada, Australia, 
and Europe (validation cohort).
PartiCiPants
500 patients from the Multicenter Randomised Clinical 
Trial of Endovascular Treatment for Acute Ischaemic 
Stroke in the Netherlands trial (derivation cohort) and 
260 patients with intracranial occlusion from the 
Interventional Management of Stroke III trial 
(validation cohort).
Main OutCOMe Measures
The primary outcome was the modified Rankin Scale 
(mRS) score at 90 days after stroke. We constructed an 
ordinal logistic regression model to predict outcome and 
treatment benefit, defined as the difference between the 
predicted probability of good functional outcome (mRS 
score 0-2) with and without intra-arterial treatment.
results
11 baseline clinical and radiological characteristics were 
included in the model. The externally validated C 
statistic was 0.69 (95% confidence interval 0.64 to 
0.73) for the ordinal model and 0.73 (0.67 to 0.79) for 
the prediction of good functional outcome, indicating 
moderate discriminative ability. The mean predicted 
treatment benefit varied between patients in the 
combined derivation and validation cohort from −2.3% 
to 24.3%. There was benefit of intra-arterial treatment 
predicted for some individual patients from groups in 
which no treatment effect was found in previous 
subgroup analyses, such as those with no or poor 
collaterals.
COnClusiOn
The proposed clinical decision tool combines multiple 
baseline clinical and radiological characteristics and 
shows large variations in treatment benefit between 
patients. The tool is clinically useful as it aids in 
distinguishing between individual patients who may 
experience benefit from intra-arterial treatment for 
acute ischaemic stroke and those who will not.
trial registratiOn
clinicaltrials.gov NCT00359424 (IMS III) and isrctn.com 
ISRCTN10888758 (MR CLEAN).
Introduction
Stroke is the second most common cause of mortality 
worldwide and the most common cause of disability in 
high income countries.1  In Western countries, 80% of 
strokes are ischaemic.2  Ischaemic strokes caused by a 
proximal occlusion in the intracranial cerebral arteries 
result in poor outcome.3 4  Intra-arterial treatment 
improves functional outcome in patients with acute 
ischaemic stroke caused by a proximal occlusion,5-11 
with a number needed to treat of 5 (odds ratio 2.35, 95% 
confidence interval 1.85 to 2.98).12  However, this is an 
average treatment effect and it is likely that treatment 
benefit will vary for individual patients.13 14  In current 
practice there is debate on the selection of candidates 
for intra-arterial treatment because of uncertainty of 
treatment benefit in specific subgroups and patients 
not included in the trials.12 15
Clinicians combine multiple characteristics in their 
clinical decision making when treating an individual 
patient. For example, consider a man aged 70 who is 
admitted 40 minutes after the onset of symptoms, 
with a severe left hemisphere ischaemic stroke and a 
National Institutes of Health Stroke Scale (NIHSS) 
score of 22, an Alberta Stroke Program Early Com-
puted Tomography Score (ASPECTS, see box 1) of 7, 
and an M1 occlusion but no collaterals on computed 
WhAT IS AlReAdy knoWn on ThIS TopIC
Intra-arterial treatment improves functional outcome in patients with acute 
ischaemic stroke caused by a proximal occlusion
In current practice there is large variation in the selection of candidates for intra-arterial 
treatment because of the uncertainty about treatment benefit in specific subgroups
WhAT ThIS STudy AddS
A newly developed clinical decision tool combines multiple baseline clinical and 
radiological characteristics and shows large variations in treatment benefit 
between patients
Selection of individual patients for intra-arterial treatment should not be based on 
single patient characteristics
This model is the first step towards individualised selection of patients for 
intra-arterial treatment for acute ischaemic stroke and may be used as tool for 
assisting clinical decision making
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tomography (CT)  angiography (see box 1). A previous 
subgroup analysis using data from the Multicenter 
Randomised Clinical Trial of Endovascular Treatment 
for Acute Ischaemic Stroke in the Netherlands (MR 
CLEAN) trial suggested no treatment effect for patients 
with no or poor collaterals.15 If this man can be treated 
soon after onset of stroke, will he benefit from 
intra-arterial treatment? Consider a woman aged 80 
with diabetes and high systolic blood pressure, who 
arrived in a primary stroke centre too late for treat-
ment with intravenous tissue plasminogen activator, 
with a NIHSS score of 22, ASPECTS of 9, and a carotid 
T occlusion with good collaterals on CT angiography. 
Should she be transferred to an intervention centre 40 
miles away if intra-arterial treatment is just possible 
within the six hour time window?
We developed and validated a clinical decision tool to 
provide individualised predictions of the effect of 
intra-arterial treatment based on multiple characteris-
tics. Such a tool may be helpful to support clinical judg-
ment when making complicated decisions on 
intra-arterial treatment.
Methods
In short, we developed a multivariable prediction 
model in patients included in the MR CLEAN trial (Mul-
ticenter Randomised Clinical Trial of Endovascular 
Treatment for Acute Ischaemic Stroke in the Nether-
lands, n=500) and validated this model in a subgroup of 
patients with an occlusion on CT angiography in the 
IMS III trial (Interventional Management of Stroke III, 
n=260). The primary outcome was the modified Rankin 
Scale (mRS) score at 90 days after stroke. We con-
structed an ordinal logistic regression model to predict 
functional outcome and treatment benefit. This benefit 
was defined as the difference between the predicted 
probability of good functional outcome (mRS score 0-2) 
with and without intra-arterial treatment. Variables 
were selected using univariable and multivariable 
selection steps (P<0.15).
Derivation cohort
We used data from all 500 patients of MR CLEAN (deri-
vation cohort) for the development of our model.5 MR 
CLEAN was a phase III multicentre clinical trial with 
randomised treatment group assignment, open label 
treatment, and blinded outcome evaluation. Intra- 
arterial treatment plus usual care was compared with 
usual care alone (control group). Usual care could 
include intravenous tissue plasminogen activator if 
 eligible. Enrolled patients were 18 years or older (no 
upper age limit), had a score of 2 or higher on the 
National Institutes of Health Stroke Scale (NIHSS) 
(range 0-42), an occlusion of the proximal internal 
carotid artery, middle cerebral artery (M1 or M2), or 
anterior cerebral artery (A1 or A2), established with CT 
angiography. The start of intra-arterial treatment had 
to be possible within six hours after stroke onset. The 
imaging committee evaluated the findings on baseline 
non-contrast CT for the ASPECTS and non-invasive 
baseline vessel imaging (CT angiography, magnetic 
resonance angiography, or digital subtraction angiog-
raphy) for the location of the occlusion and collateral 
score.
More detailed information about MR CLEAN can be 
found in the study protocol and the publication of the 
main results.5 18
Model development
Patient characteristics obtained before treatment that 
are expected to predict outcome or to interact with 
treatment, based on expert opinion or recent literature, 
were specified in advance in our statistical analysis 
plan.19  We used ordinal logistic regression modelling, 
which assumes proportional odds, to test the effect of 
age, baseline NIHSS score, systolic blood pressure, 
treatment with intravenous tissue plasminogen activa-
tor, history of ischaemic stroke, atrial fibrillation, diabe-
tes mellitus, pre-stroke mRS score, ASPECTS, location 
of occlusion, collateral score, and time to treatment, as 
well as the corresponding interactions with treatment. 
The primary outcome was the mRS score, a 7 point scale 
ranging from 0 (no symptoms) to 6 (death), at 90 days 
after stroke.20 For additional analyses, we derived the 
probabilities for good functional outcome (mRS score 
0-2) from the ordinal model. Treatment benefit was 
defined as the difference between the predicted proba-
bility of good functional outcome with and without 
intra-arterial treatment.
In our final multivariable model we selected the 
main effects or interaction terms with a P value of <0.15 
in univariable and multivariable analyses. Location of 
occlusion was analysed categorically and ASPECTS 
and collateral score were analysed continuously. Con-
tinuous variables were not dichotomised. Non-linear-
ity of continuous variables was tested with restricted 
cubic spline functions.21 In the final model we used 
restricted cubic spline functions for age and systolic 
blood pressure. As a measure of time to treatment we 
used the time from stroke onset to groin puncture. 
Since groin puncture was not performed in control par-
ticipants, time to groin puncture was not observable in 
the control arm. Single imputation based on regression 
using age, NIHSS score, transfer between hospitals, 
hospital of first presentation, and time to randomisa-
tion, was used to assign time to expected groin punc-
ture (R2=0.89). Since all other variables were more than 
98% complete within the derivation cohort, we used 
simple imputation by the mean for continuous 
box 1: Descriptions of asPeCts and collateral score
asPeCts
A quantitative grading system to assess early ischaemic changes on a non-contrast CT 
scan. Scores ranges from 0 to 10, with 10 points for a normal CT scan and 1 point 
subtracted for every defined region with evidence of early ischaemic changes16
Collateral score
A 4 point scale to grade the collateral flow of the occluded territory on vessel imaging, 
with 0 representing absent collateral flow, 1 representing poor collateral flow (<50% 
filling), 2 representing moderate collateral flow (between 50% and 100% filling), and 
3 representing good collateral flow (100% filling)17
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 variables and simple imputation by the mode for cate-
gorical variables.
Internal validation with bootstrapping was used to 
estimate the degree of optimism in the final model. To 
correct for this optimism we reduced the regression 
coefficients using penalised regression.21 22  Coefficients 
of non-linear terms and interaction terms were reduced 
with a larger penalty than the main effects.22
external validation
External validation of our model was performed in the 
IMS III trial.23  The IMS III trial (n=656) was a phase III 
multicentre clinical trial with randomised treatment 
group assignment, open label treatment, and blinded 
outcome evaluation. The trial tested the approach of 
intravenous tissue plasminogen activator followed by 
endovascular treatment compared with standard intra-
venous tissue plasminogen activator. Further details 
on  the methods used in the trial have been reported 
extensively.23 24
We included patients with proved occlusion in the 
anterior circulation on non-invasive vessel imaging 
and an available mRS score at 90 days in the valida-
tion cohort (n=260). Missing collateral scores 
because of insufficient CT angiography imaging 
(n=68) were replaced by single imputation with 
regression using age, history of diabetes mellitus, 
and presence of  internal carotid T occlusion. Single 
imputation for time to groin puncture (n=102, primar-
ily control patients) was performed using age, NIHSS 
score, time to randomisation, and transfer between 
hospitals. All other variables were more than 98% 
complete. Missing values were imputed with the 
mean for continuous variables or the mode for cate-
gorical variables.
Model performance in the validation cohort was 
expressed by discrimination and calibration. Discrimi-
nation was quantified with the concordance or C statis-
tic, which varies between 0.5 for a non-informative 
model and 1 for a perfectly discriminating model.25 We 
calculated the general C statistic of our ordinal model 
and an additional C statistic for the predictions of good 
functional outcome (mRS score 0-2).
Calibration refers to the level of agreement between 
predicted risks and observed outcome; this was 
assessed graphically with a validation plot for the 
 prediction of good functional outcome (mRS score 0-2) 
expressed as calibration slope and intercept. The cali-
bration slope describes the effect of the predictors in 
the validation sample versus the derivation sample, 
and is ideally equal to 1. The intercept indicates whether 
predictions are systematically too high or too low, and 
should ideally be zero.26
After external validation, the regression coeffi-
cients were fitted on a dataset combining all patients 
in the derivation and validation cohort. To assess if 
our model could be used to select individual patients 
for intra-arterial treatment, we estimated the individ-
ual predictions for all 760 patients included in this 
combined dataset. We created a scatter plot with the 
predicted probabilities of good functional outcome 
(mRS score 0-2) for these patients without intra-arte-
rial treatment on the x axis and the predicted 
 probabilities with intra-arterial treatment on the y 
axis. We made  additional plots for the predictions of 
patients with no or poor collaterals and patients with 
low ASPECTS, since prespecified subgroup analyses 
showed that these groups had no or limited benefit of 
treatment.
All statistical analyses were performed with R statis-
tical software (version 3.2.2) and the rms library (ver-
sion 4.4-0). The web application was developed with 
the R Shiny package (shiny version 0.13.0).
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for design or implementation of the 
study. No patients were asked to advise on interpreta-
tion or writing up of results. There are plans to dissemi-
nate the results of the research to the relevant patient 
community.
Results
Table 1 shows that the baseline patient characteristics 
and important characteristics of workflow and outcome 
were similar between the derivation cohort (n=500) and 
validation cohort (n=260). The validation cohort was 
somewhat more homogeneous, by not including 
patients with baseline disability (premorbid mRS score 
≥3) or patients not treated with intravenous tissue plas-
minogen activator.
Most variables were predictors of outcome (table 2 ). 
The strongest predictors in multivariable analysis were 
age (P<0.001), baseline NIHSS score (P<0.001), systolic 
blood pressure (P<0.001), history of ischaemic stroke 
(P=0.03), diabetes mellitus (P=0.02), pre-stroke mRS 
score (P=0.003), ASPECTS (P=0.001), location of occlu-
sion (P=0.03), and collateral score (P<0.001). Interac-
tions with relative treatment effect were found in 
univariable analysis for history of ischaemic stroke, 
atrial fibrillation, time to groin puncture, and collateral 
score (all P≤0.10, fig 1). In the multivariable model, the 
effects of intra-arterial treatment were similar to the 
univariable analysis, with larger effects in patients 
without previous ischaemic stroke (P=0.07), patients 
with better collateral scores (P=0.07), and patients with 
shorter times to groin puncture (P=0.13). Atrial fibrilla-
tion was not significant in multivariable analysis as 
either a main effect (P=0.67) or interaction effect 
(P=0.27), and was therefore excluded from the model.
The final multivariable model included age, baseline 
NIHSS score, systolic blood pressure, treatment with 
intravenous tissue plasminogen activator, history of 
ischaemic stroke, diabetes mellitus, pre-stroke mRS 
score, ASPECTS, location of occlusion, collateral score, 
and time from stroke onset to groin puncture. We added 
terms representing the interaction between treatment 
and each of previous stroke, collateral score, and time 
to groin puncture. The internally validated C statistic 
for ordinal outcome was 0.74 without interaction terms 
and this increased to 0.75 by adding interaction with 
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treatment. The C statistic for good functional outcome 
was 0.79.
external validation
Similar effects were found for most variables in the 
 validation cohort except for systolic blood pressure, 
diabetes mellitus, and the interaction between history 
of ischaemic stroke and treatment effect. The exter-
nally validated C statistic was 0.69 (95% confidence 
interval 0.64 to 0.73) for the ordinal model and 0.73 
(0.67 to 0.79) for the prediction of good functional out-
come (fig 2).
The expected benefit of intra-arterial treatment var-
ied largely between patients in the combined derivation 
and validation cohort (fig 3  top graph). Mean predicted 
absolute treatment benefit was an 11.8% higher 
 probability of mRS score 0-2 compared with the proba-
bility without intra-arterial treatment, and varied from 
−2.3% to 24.3% between individual patients in the com-
bined derivation and validation cohort. The individual 
predictions for patients with no or poor collaterals 
(score 0 or 1) or low ASPECTS (score 0-5) illustrate the 
substantial variation in outcome and treatment benefit 
in these groups (fig 3 middle and bottom graphs). For 
some patients, who have multiple characteristics that 
negatively affect treatment benefit, the model predicts 
no benefit or even harm.
We calculated the predicted probabilities of good 
functional outcome with and without intra-arterial 
treatment for the two patients described in the intro-
duction (fig 4). The first patient is expected to benefit 
from intra-arterial treatment despite absent collaterals 
and moderate ASPECTS. The probability of achieving a 
good functional outcome increases by 11 percentage 
points, from 16% without intra-arterial treatment to 
27% with intra-arterial treatment. The predictions for 
the second patient illustrate that a good collateral score 
does not guarantee a large treatment benefit. The 80 
year old patient has a low probability of achieving a 
good functional outcome (3% without intra-arterial 
treatment and 5% with intra-arterial treatment), with 
some shift on the total mRS scale.
table 1 | Overview of derivation and validation cohorts. values are numbers (percentages) unless stated otherwise
Characteristics
Derivation  
cohort  
(n=500)
validation  
cohort  
(n=260)
Mean (SD) age (years) 65 (14) 67 (12)
Men 292 (58) 135 (52)
Baseline score (interquartile range) on National Institutes of Health Stroke Scale 18 (14-22) 17 (14-21)
Mean (SD) systolic blood pressure (mm Hg) 145 (25) 149 (26)
Treatment with intravenous tissue plasminogen activator 445 (89) 260 (100)
Allocation to intra-arterial treatment 233 (47) 174 (67)
Medical history:
 Ischaemic stroke 54 (11) 28 (11)
 Atrial fibrillation 135 (27) 89 (35)
 Diabetes mellitus 68 (14) 49 (19)
 Pre-stroke mRS score:
  0 404 (81) 231 (89)
  1 50 (10) 22 (8)
  2 25 (5) 7 (3)
  ≥3 21 (4) 0
Imaging:
 Alberta Stroke Program Early CT score (interquartile range) on non-contrast CT 9 (8-10) 8 (6-9)
Location of occlusion on non-invasive vessel imaging:
 Internal carotid artery with terminal segment 138 (28) 66 (25)
 M1 319 (64) 144 (55)
 M2 39 (8) 50 (19)
 A1 3 (1) 0
Minutes (interquartile range) to stroke onset:
 Randomisation 200 (150-261) 143 (120-170)
 Groin puncture 260 (210-311) 205 (168-235)
 Reperfusion 340 (274-395) 275 (238-319)
Outcome:
 Recanalisation (mTICI 2B/3) 116 (59) 69 (45)
 mRS score at 90 days:
  0 7 (1) 27 (10)
  1 36 (7) 46 (18)
  2 84 (17) 39 (15)
  3 87 (17) 36 (14)
  4 133 (27) 44 (17)
  5 45 (9) 18 (7)
  6 (mortality) 108 (22) 50 (19)
CT=computed tomography; mRS=modified Rankin Scale; mTICI=modified thrombolysis in cerebral infarction scale.
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We implemented our model in a web application that 
provides predictions of outcome for individual patients 
with acute ischaemic stroke based on baseline clinical 
and radiological characteristics for use in clinical prac-
tice. It shows bar charts with the expected distribution 
of mRS categories with and without intra-arterial treat-
ment, the predicted probabilities of good functional 
outcome, and the predicted absolute treatment benefit 
(fig 4). This web application was made accessible online 
at www.mrpredicts.com.
table 2 | Main effects in derivation cohort (n=500)
variables
univariable model Multivariable model
Common odds 
ratio* (95% Ci) P value
Common odds 
ratio* (95% Ci) P value
Intra-arterial treatment 1.66 (1.21 to 2.28) 0.002 1.86 (1.34 to 2.59) <0.001
Age per year:
 <65 0.97 (0.95 to 0.99)
<0.001
1.00 (0.97 to 1.02)
<0.001
 ≥65 0.92 (0.89 to 0.94) 0.92 (0.89 to 0.95)
Baseline National Institutes of Health Stroke Scale score per point 0.91 (0.88 to 0.94) <0.001 0.93 (0.90 to 0.96) <0.001
Systolic blood pressure per 10 mmHg:
 <130 mm Hg 1.12 (0.88 to 1.41)
<0.001
1.26 (0.99 to 1.61)
<0.001
 ≥130 mm Hg 0.76 (0.70 to 0.83) 0.77 (0.70 to 0.85)
Treatment with intravenous tissue plasminogen activator 1.85 (1.12 to 3.08) 0.02 1.62 (0.94 to 2.79) 0.08
History of ischaemic stroke 0.48 (0.29 to 0.80) 0.005 0.53 (0.31 to 0.92) 0.03
Atrial fibrillation 0.52 (0.36 to 0.73) <0.001 0.92 (0.62 to 1.36) 0.67
Diabetes mellitus 0.37 (0.23 to 0.59) <0.001 0.55 (0.33 to 0.90) 0.02
Pre-stroke mRS score 0.63 (0.52 to 0.77) <0.001 0.72 (0.58 to 0.90) 0.003
Alberta Stroke Program Early CT score per point 1.16 (1.07 to 1.26) <0.001 1.16 (1.06 to 1.28) 0.001
Location of occlusion on non-invasive imaging:
 Internal carotid artery with terminal segment 1.0 (reference)
0.02
1.0 (reference)
0.03 M1 1.53 (1.08 to 2.17) 1.43 (0.98 to 2.07)
 M2 2.11 (1.15 to 3.88) 2.35 (1.20 to 4.60)
Collateral score 1.95 (1.62 to 2.36) <0.001 1.61 (1.31 to 1.96) <0.001
Time from stroke onset to groin puncture per 30 minutes 0.94 (0.88 to 1.00) 0.07 0.93 (0.86 to 1.00) 0.04
CT=computed tomography; mRS=modified Rankin Scale.
Presented common odds ratios reflect the effect on the reversed mRS.
*Value >1 corresponds to better functional outcome.
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Fig 1 | univariable interaction effects in derivation cohort (n=500). interaction with treatment is expressed as log odds for 
good functional outcome (modified rankin scale score 0-2) with and without intra-arterial treatment on the y axis. 
variables on x axis are expressed continuously (time to groin puncture) or categorically (previous stroke, atrial fibrillation, 
and collateral score)
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discussion
We developed and externally validated a clinical 
decision tool to predict the benefit of intra-arterial 
treatment for individual patients with acute isch-
aemic stroke, based on multiple patient characteris-
tics. The predicted treatment benefit varied 
substantially between individual patients with differ-
ent risk profiles.
strengths and weaknesses in relation to other 
studies
Two risk scores have been described previously for the 
prediction of functional outcome after intra-arterial 
treatment.27 28  These scores are of limited value 
because they were developed on older cohorts of 
patients who were treated before the introduction of 
stent retrievers and contain only a small number of 
clinical variables. Furthermore, they do not provide 
individual predictions and most of the variables and 
outcome measures in these studies had been dichoto-
mised, which is considered to be statistically ineffi-
cient and biologically implausible.29  Our model 
combines 11 baseline clinical and radiological charac-
teristics simultaneously to provide individualised pre-
dictions of the effect of intra-arterial treatment. In 
contrast, conventional subgroup analyses focus 
mainly on predictive effects and assess the effect of 
only one variable at a time. Previous  subgroup analy-
ses of trials on intra-arterial treatment have tested 
whether there are differences in effect of such treat-
ment based on time to treatment,30-34  stroke sever-
ity,12 35  and collateral score.15  Analysing one variable 
at a time may provide mechanistic insights to inform 
future studies and shape clinical considerations. How-
ever, they are of limited value in individual patient 
care, because treatment benefit is influenced by multi-
ple individual factors simultaneously.13 14  Further-
more, even with similar relative treatment effects, 
individual patients may have different absolute treat-
ment effects owing to different baseline risks. More 
targeted individual treatment decisions can be 
obtained by using a more complex multivariable mod-
elling approach to identify individual patients with 
large or small expected treatment benefit.13
We found modest interaction with treatment for his-
tory of ischaemic stroke, collateral score, and time from 
stroke onset to groin puncture. For collateral score and 
time to groin puncture, interaction with effect of 
intra-arterial treatment was already shown in previous 
subgroup analyses.15 30 Both variables are clinically 
likely to cause an interaction with intra-arterial treat-
ment. However, previous stroke has not been studied 
for interaction with treatment before, and was an unex-
pected finding in our study. It may be a chance finding, 
since it was not reproduced in the validation cohort and 
we have no clinical explanation. When the regression 
coefficients were fitted on data of the combined deriva-
tion and validation cohort and the coefficients of inter-
action terms were reduced to prevent overfitting, the 
interaction effect for previous stroke in the final model 
was small. Further validation should reveal whether the 
relative effect of intra-arterial treatment is modified by 
experience of a previous stroke.
Our study has several limitations. The discrimina-
tive ability of the model in the external validation was 
modest. It should be emphasised that the C statistic 
for the ordinal outcome is a conservative measure. It 
assesses discrimination between exact categories of 
the mRS, instead of discrimination between two 
groups with different outcome (eg, mRS score 0-2 v 
mRS score 3-6). Externally validated C statistics of all 
cut-offs were better than the ordinal C statistic (eg, 
0.73 for good functional outcome and 0.75 for mortal-
ity). Nevertheless, the relatively small sample size 
and inclusion of interaction terms in the model may 
have resulted in some optimism and overfitting, 
despite shrinkage of the regression coefficients. The 
calibration was also suboptimal; despite the fact that 
most patients were treated with first generation 
thrombectomy devices, patients in the Interventional 
Management of Stroke III trial (IMS III) had a better 
outcome than predicted by our model. This could be 
explained by the patient selection in IMS III (eg, pre-
morbid mRS score 0-2, age <82 years, treatment with 
intravenous tissue plasminogen activator),36 which 
resulted in a better prognosis overall. Patients in the 
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Fig 2 | Calibration plot for predicted good functional 
outcome, defined as modified rankin scale (mrs) score 
0-2, in validation cohort (n=260). the calibration slope 
reflects the strength of predictors. the calibration 
intercept reflects the calibration in the large, indicating 
whether predicted probabilities are systematically too low 
or too high. the overall observed proportion of patients 
with mrs score 0-2 in the validation cohort was higher as 
to be expected using our model. the linear bar chart shows 
the distribution of patients with (=1) or without (=0) an 
observed outcome of mrs score 0-2. Discrimination 
between low and high likelihood of good functional 
outcome was moderate (C statistic 0.73, 95% confidence 
interval 0.67 to 0.79)
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IMS III control group had better outcomes than 
patients in the control group in the Multicenter Ran-
domised Clinical Trial of Endovascular Treatment for 
Acute Ischaemic Stroke in the Netherlands (MR 
CLEAN) trial (mRS score 0-2=39% (IMS III with occlu-
sion on CT angiography) v 19% (MR CLEAN)), leading 
to inadequate calibration of our model.5 36
implications for clinicians
Despite its limitations, the currently developed model 
is the first to predict the effect of intra-arterial treat-
ment for individual patients on arrival at the emer-
gency department. When compared with other 
models used in neurovascular practice, HAS-BLED (C 
statistic 0.65) and CHA2DS2-VASc (0.61), it performs 
accurately.37 38  The predictions made by our decision 
tool often agree with clinical intuition, which should 
not be surprising.  However, estimates derived from 
large datasets are preferable to the subjective opinion 
of a doctor, whose experience, no matter how vast, 
can never match the information contained in large 
datasets.39
Currently, some centres withhold intra-arterial 
treatment in specific subgroups of patients (eg, low 
ASPECTS, no collaterals, age >80 years, or M2 occlu-
sion). Indeed, our model predicts no benefit of 
intra-arterial treatment for some patients, especially 
when a patient has more than one characteristic that 
negatively affects the effect of intra-arterial treat-
ment. The decision not to treat may be particularly 
relevant in patients who have to be transferred to an 
intervention centre. The model may help to identify 
patients without expected benefit of intra-arterial 
treatment and topple the balance in favour of no 
treatment. More importantly, our study shows that 
treatment should not be withheld based on one char-
acteristic. Some patients belonging to one of the sub-
groups that are considered as having no benefit of 
intra-arterial treatment, such as poor collaterals or 
low ASPECTS, may still benefit from intra-arterial 
treatment substantially if other characteristics are 
favourable. This emphasises the importance of mak-
ing personalised treatment decisions, instead of 
using average treatment effects, and shows the need 
for combining multiple clinical and radiological 
baseline characteristics instead of withholding treat-
ment based on one characteristic.40
This is the first model for intra-arterial treatment 
decision making. The predictions of our model should 
be considered as a starting point for clinical decision 
making, and not as a final recommendation. Our model 
was developed using the MR CLEAN database, consist-
ing of an unselected population with few selection cri-
teria. Therefore, our model is likely applicable in 
centres that use few clinical and radiological selection 
criteria. Future analyses within larger studies may 
refine the current recommendations and improve the 
validity of the model.
Conclusion
The proposed clinical decision tool combines multiple 
baseline clinical and radiological characteristics and 
shows large variations in treatment benefit between 
patients. The tool is clinically useful as it aids in identi-
fying individual patients who may benefit from intra-ar-
terial treatment for acute ischaemic stroke.Probability of good functional outcome without IAT
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Fig 3 | (a) Predicted 
probabilities of good 
functional outcome 
(modified rankin scale 
(mrs) score 0-2) for all 
individual patients in 
combined derivation and 
validation cohort (n=760). 
each dot represents one 
individual patient, with the 
probability of good 
functional outcome (mrs 
score 0-2) without 
intra-arterial treatment 
(iat) expressed on x axis, 
and probability for good 
functional outcome with iat 
on y axis. above the 
diagonal line the predicted 
probability of good 
functional outcome with iat 
is higher than that without 
iat. the farther above this 
line, the larger the 
predicted effect of 
treatment. (b) Patients 
highlighted with no or poor 
collaterals (score 0-1). (C) 
Patients highlighted with 
low alberta stroke Program 
early Ct score (asPeCts, 
score 0-5)
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Clinical decision tool for intra arterial treatment in acute ischaemic stroke
Patient characteristics
Predicted modied Rankin Scale (mRS) scores at 90 days
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Fig 4 | a stylised representation of the clinical decision tool. baseline characteristics and predicted probabilities of good 
functional outcome (modified rankin scale (mrs) score 0-2) for two examples (see introduction). asPeCt=alberta stroke 
Program early Computed tomography score; iat=intra-arterial treatment; nihss=national institutes of health stroke 
scale; iCa=internal carotid artery; Cta=computed tomography angiography
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